| Medical Mutual | Bevacizumab: Alymsys® (Intravenous) (EOV) | 2026-07-01 |
| Medical Mutual | Oncology Value (Intravenous) (EOV) | 2026-07-01 |
| Medical Mutual | Oncology Value (Intramuscular) | 2026-07-01 |
| Medical Mutual | Oncology Value: Golimumab: (Intravenous) | 2026-07-01 |
| Medical Mutual | Enhanced Oncology Value: Imfinzi® (durvalumab) (Intravenous) (EOV) | 2026-07-01 |
| Medical Mutual | Oncology Value: Imjudo® (tremelimumab-actl) (Intravenous) | 2026-07-01 |
| Medical Mutual | Oncology Value: Jemperli (dostarlimab-gxly) (Intravenous) (EOV) | 2026-07-01 |
| Medical Mutual | Krystexxa® (pegloticase) (Intravenous) | 2026-07-01 |
| Medical Mutual | Oncology Value: Levoleucovorin: (Intravenous) | 2026-07-01 |
| Medical Mutual | Oncology Value: Libtayo® (cemiplimab-rwlc) (Intravenous) | 2026-07-01 |